Korea's SK Biopharmaceuticals Quietly Sets Its Eyes On The U.S. - And China
This article was originally published in PharmAsia News
SEOUL - After completion of preclinical trials with Chinese contract research organization Shanghai Medicilon Inc., Korea's SK Biopharmaceuticals Co. said Oct. 18 that it plans to file an Investigational New Drug application to conduct clinical trials in the U.S. - possibly in 2014 - for a compound to treat depression and manic bipolar disorder
You may also be interested in...
The Korea Drug Development Fund and the Health Ministry are pursuing two separate projects, but targeting the same goal of helping R&D-focused companies.
SK Chemicals has signed a deal with 12 European pharmaceutical companies to sell its Alzheimer’s patch SID710, which it says, will be the first generic patch of Novartis’ Exelon in Europe.
SEOUL - South Korea's Hanwha Chemical Corp. - a latecomer to the biopharma industry - is trying to carve out a share of the biosimilars market with a version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept), which is to be sold by Merck & Co. outside of Korea